z-logo
open-access-imgOpen Access
Protection against Alloxan-Induced Diabetes by Diethyldithiocarbamate and Disulfiram in Mice
Author(s) -
Tohru Masukawa,
Kunio Nakanishi
Publication year - 1994
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.64.141
Subject(s) - alloxan , disulfiram , chemistry , antagonist , endocrinology , mechanism of action , diabetes mellitus , medicine , pharmacology , biochemistry , receptor , in vitro
Diethyldithiocarbamate (DEDC, 0.25-2.00 mmol/kg) injected into mice at 0.5 hr prior to alloxan administration dose-dependently protected the mice against the diabetogenic actions of 75 mg/kg alloxan. Disulfiram (DS, 0.50-2.00 mmol/kg), a corresponding disulfide form, also exhibited similar protection. The maximum effect of DEDC was found by dosing at 0.5 hr prior to alloxan, and the effect afforded by DEDC pretreatment persisted up to 3 hr, whereas the effect of DS was exhibited when the compound was given 0.5 hr prior to alloxan. Of the metabolites of DEDC, diethylamine and carbon disulfide had no effect. At 0.5 hr after injection, DEDC alone had a potent increasing ability on blood glucose in a dose-dependent manner, but DS was less potent. Mannoheptulose, an antagonist of glucose action at pancreatic beta-cells, when given 24 min after DEDC and 6 min before alloxan, eliminated the DEDC-induced protection. Fasted mice did not exhibit hyperglycemia at 0.5 hr after DEDC injection, and alloxan given at that time produced diabetes. These findings indicate that DEDC itself protected mice from alloxan-induced diabetes by the indirect mechanism of producing hyperglycemia at the time of alloxan administration. The anti-diabetogenic action of low doses of DS and DEDC, in animals lacking hyperglycemia at the time of alloxan injection, is likely based on a mechanism other than one involving hyperglycemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here